Artrya Limited (AU:AYA) has released an update.
Artrya Limited has made significant strides by submitting a 510(k) application to the US FDA for its Salix® Coronary Anatomy software, aiming to penetrate the US market. The company successfully integrated its software into Tanner Health System, marking a key step in its pre-FDA clearance process, and reported its first revenues from processing over 500 CCTA scans. With $6.5 million in cash as of September 2024, Artrya continues to focus on cost management and strategic growth in the cardiovascular technology sector.
For further insights into AU:AYA stock, check out TipRanks’ Stock Analysis page.